News

Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent ...
WILMINGTON, Del., September 15, 2024--Positive results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with chemotherapy demonstrated a statistically ...
Two-year EFS with perioperative durvalumab was 67.4% versus 58.5% in the group of patients who received FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) and placebo, with median EFS not ...
IMFINZI® (durvalumab) perioperative regimen improved event-free survival and overall survival across muscle-invasive bladder cancer patients regardless of complete pathology response status in ...
Earlier this year, the FDA approved durvalumab (Imfinzi; AstraZeneca) in combination with chemotherapy for adult patients with resectable early-stage (IIA-IIIB) non–small cell lung cancer (NSCLC ...
A total of 474 participants were randomly assigned to the durvalumab group, and 474 to the placebo group (median follow-up, 31.5 months; interquartile range, 26.7 to 36.6).
Cambridge: AstraZeneca has received approval for Imfinzi (durvalumab) in the European Union (EU) for the treatment of adult ...
Bonilla, MD, MSEd, discusses findings from the MATTERHORN trial in patients with resectable gastric or gastroesophageal junction adenocarcinoma.
IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC ...
AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi ...
AstraZeneca Pharma India gets CDSCO approval for treating endometrial cancer in the country: Our Bureau, Bengaluru Wednesday, July 2, 2025, 15:15 Hrs [IST] AstraZeneca Pharma Indi ...
Two-year EFS with perioperative durvalumab was 67.4% versus 58.5% in the group of patients who received FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) and placebo, with median EFS not ...